S&P 500   4,587.24 (+0.78%)
DOW   35,698.86 (+0.59%)
QQQ   382.52 (+0.66%)
AAPL   151.99 (+2.11%)
MSFT   322.03 (-0.35%)
FB   312.78 (+0.18%)
GOOGL   2,909.16 (-0.52%)
TSLA   1,062.65 (+2.39%)
AMZN   3,411.73 (+0.57%)
NVDA   247.66 (+1.29%)
BABA   169.84 (+0.36%)
NIO   39.66 (+0.89%)
CGC   13.10 (+2.50%)
GE   104.29 (+0.42%)
AMD   122.91 (+0.52%)
MU   69.43 (+1.74%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.94 (+1.46%)
DIS   169.58 (+0.02%)
PFE   43.17 (+0.47%)
BA   205.65 (-0.46%)
AMC   35.73 (+2.79%)
S&P 500   4,587.24 (+0.78%)
DOW   35,698.86 (+0.59%)
QQQ   382.52 (+0.66%)
AAPL   151.99 (+2.11%)
MSFT   322.03 (-0.35%)
FB   312.78 (+0.18%)
GOOGL   2,909.16 (-0.52%)
TSLA   1,062.65 (+2.39%)
AMZN   3,411.73 (+0.57%)
NVDA   247.66 (+1.29%)
BABA   169.84 (+0.36%)
NIO   39.66 (+0.89%)
CGC   13.10 (+2.50%)
GE   104.29 (+0.42%)
AMD   122.91 (+0.52%)
MU   69.43 (+1.74%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.94 (+1.46%)
DIS   169.58 (+0.02%)
PFE   43.17 (+0.47%)
BA   205.65 (-0.46%)
AMC   35.73 (+2.79%)
S&P 500   4,587.24 (+0.78%)
DOW   35,698.86 (+0.59%)
QQQ   382.52 (+0.66%)
AAPL   151.99 (+2.11%)
MSFT   322.03 (-0.35%)
FB   312.78 (+0.18%)
GOOGL   2,909.16 (-0.52%)
TSLA   1,062.65 (+2.39%)
AMZN   3,411.73 (+0.57%)
NVDA   247.66 (+1.29%)
BABA   169.84 (+0.36%)
NIO   39.66 (+0.89%)
CGC   13.10 (+2.50%)
GE   104.29 (+0.42%)
AMD   122.91 (+0.52%)
MU   69.43 (+1.74%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.94 (+1.46%)
DIS   169.58 (+0.02%)
PFE   43.17 (+0.47%)
BA   205.65 (-0.46%)
AMC   35.73 (+2.79%)
S&P 500   4,587.24 (+0.78%)
DOW   35,698.86 (+0.59%)
QQQ   382.52 (+0.66%)
AAPL   151.99 (+2.11%)
MSFT   322.03 (-0.35%)
FB   312.78 (+0.18%)
GOOGL   2,909.16 (-0.52%)
TSLA   1,062.65 (+2.39%)
AMZN   3,411.73 (+0.57%)
NVDA   247.66 (+1.29%)
BABA   169.84 (+0.36%)
NIO   39.66 (+0.89%)
CGC   13.10 (+2.50%)
GE   104.29 (+0.42%)
AMD   122.91 (+0.52%)
MU   69.43 (+1.74%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.94 (+1.46%)
DIS   169.58 (+0.02%)
PFE   43.17 (+0.47%)
BA   205.65 (-0.46%)
AMC   35.73 (+2.79%)
NASDAQ:ABOS

Acumen Pharmaceuticals Stock Forecast, Price & News

$14.78
+0.19 (+1.30 %)
(As of 10/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.78
$14.80
50-Day Range
$13.09
$18.85
52-Week Range
$12.70
$26.98
Volume
143 shs
Average Volume
176,401 shs
Market Capitalization
$598.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ABOS News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Acumen Pharmaceuticals logo

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABOS
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.44 million

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$598.12 million
Next Earnings Date
11/15/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.60 out of 5 stars

Medical Sector

984th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

154th out of 197 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Acumen Pharmaceuticals (NASDAQ:ABOS) Frequently Asked Questions

Is Acumen Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Acumen Pharmaceuticals stock.
View analyst ratings for Acumen Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Acumen Pharmaceuticals?

Wall Street analysts have given Acumen Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acumen Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acumen Pharmaceuticals?

Acumen Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 958,100 shares, an increase of 41.3% from the September 30th total of 677,900 shares. Based on an average daily trading volume, of 187,900 shares, the days-to-cover ratio is presently 5.1 days. Currently, 3.4% of the shares of the company are sold short.
View Acumen Pharmaceuticals' Short Interest
.

When is Acumen Pharmaceuticals' next earnings date?

Acumen Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Acumen Pharmaceuticals
.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) announced its quarterly earnings data on Sunday, August, 15th. The company reported ($7.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $7.74.
View Acumen Pharmaceuticals' earnings history
.

What price target have analysts set for ABOS?

4 analysts have issued 1-year price objectives for Acumen Pharmaceuticals' stock. Their forecasts range from $20.00 to $27.00. On average, they expect Acumen Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 71.4% from the stock's current price.
View analysts' price targets for Acumen Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Acumen Pharmaceuticals' key executives?

Acumen Pharmaceuticals' management team includes the following people:
  • Mr. Daniel J. O'Connell M.B.A., Chief Exec. Officer, Pres and Director (Age 51, Pay $336k)
  • Mr. Russell Barton M.S., Chief Operating Officer (Age 63, Pay $223.68k)
  • Dr. Eric Siemers M.D., Chief Medical Officer (Age 66, Pay $237.6k)
  • Mr. Matt Zuga, CFO & Chief Bus. Officer

When did Acumen Pharmaceuticals IPO?

(ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share.

What is Acumen Pharmaceuticals' stock symbol?

Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."

When does the company's lock-up period expire?

Acumen Pharmaceuticals' lock-up period expires on Tuesday, December 28th. Acumen Pharmaceuticals had issued 9,999,999 shares in its initial public offering on July 1st. The total size of the offering was $159,999,984 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acumen Pharmaceuticals' stock price today?

One share of ABOS stock can currently be purchased for approximately $14.59.

How much money does Acumen Pharmaceuticals make?

Acumen Pharmaceuticals has a market capitalization of $590.43 million and generates $1.44 million in revenue each year.

How many employees does Acumen Pharmaceuticals have?

Acumen Pharmaceuticals employs 2,021 workers across the globe.

What is Acumen Pharmaceuticals' official website?

The official website for Acumen Pharmaceuticals is www.acumenpharm.com.

How can I contact Acumen Pharmaceuticals?

The company can be reached via phone at 925-368-8508.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.